Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab (Sanofi) cemented its position as the top-selling inflammatory illness medication with its first-in-class IL-4Rα antagonist. In 2024, it generated $14.179 billion in sales (23% YoY growth).

Please provide your email address to receive an email when new articles are posted on . Dupilumab and mepolizumab are the only FDA-approved biologics for adults with COPD and an eosinophilic phenotype ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, breaks down how to communicate the value of ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Biological drugs have been a game-changer for people with severe asthma, helping them breathe easier and live more ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.